Gout

ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka

Links:

https://bit.ly/3mX32qi

Dr. John Cush @RheumNow( View Tweet )

Jan 05, 2022

Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Links:

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021

SGLT2 Inhibitors in Type 2 Diabetes Lowers Gout Risk
Save

Jack Cush, MD

Dec 15, 2021

A recent study of drugs used in type 2 diabetes (T2DM) shows that SGLT2 inhibitors have a lower risk for gout compared with those receiving DPP4 inhibitors.

The sodium–glucose cotransporter-2 inhibitors (e.g., Invokana, Jardiance, Farxiga) are reported to lower the risk of gout in

Read Article

Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

Links:

https://bit.ly/3yomMYo

Dr. John Cush @RheumNow( View Tweet )

Dec 13, 2021

Links:

https://bit.ly/3y7qaqk

Dr. John Cush @RheumNow( View Tweet )

Dec 10, 2021

Genes and Obesity Tied to Higher Gout Risk in Women
Save

Jack Cush, MD

Dec 09, 2021

Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.

Analysis of data from the Nurses' Health Study (NHS) found that the relative risk for incident

Read Article

#ACR21 is complete--view all our RheumNow's coverage.https://t.co/wkZ66lcB44

Links:

https://bit.ly/3DGlJol

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021

Geriatric Rheumatology:Improving care of aging patients Dr.Kathryn Dao ( @KDAO2011) moderates a panel w/ Drs.Una Makris, Katherine Wysham, Sebastian Sattui + Devyani Misra, as they discuss aspects of improving care of/outcomes for aging patients. #ACR21 https://t.co/lF3yUZBEkd https://t.co/hYufA8ptqj

Links:

https://bit.ly/3DI0KRS

Dr. John Cush @RheumNow( View Tweet )

Nov 19, 2021

Data from ASN Kidney Wk 2021; US Renal Data System of 275,651 dialysis pts - 15% had gout Vs 85% without gout; Gout pts were older, more male, obese, had more hospitalizations (66 vs 57%), mortality, more CVD, PVD and MI https://t.co/m1d0SJEJjw

Links:

https://bit.ly/32fzVH5

Dr. John Cush @RheumNow( View Tweet )

Nov 18, 2021

Day 4 Report from ACR21
Save

Jack Cush, MD

Nov 10, 2021

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article

Gout being sneaky🧐 Common consult question is "infection or flare?" in patients with gout. @ACR21 ABS0467 w/ Dr Michael Toprover: 🔸Calibrating DECT for LS-spine in gout patients. 🔹DECT signal = MSU deposition? 🔸Future data on back pain/gout flare/MSU🤞? @RheumaRepublic https://t.co/aDCusqBk8G

Bonnia Liu @bonnialiu( View Tweet )

Nov 09, 2021

Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY

Tuhina Neogi, MD, PhD @Tuhina_Neogi( View Tweet )

Nov 09, 2021

We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2

Richard Conway @RichardPAConway( View Tweet )

Nov 09, 2021

Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416

Janet Pope @Janetbirdope( View Tweet )

Nov 09, 2021

#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout ⭐️Effectively brought down serum uric acid <5, dose-dependent ⭐️10% pts gout flare with urate lowering @Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ

Links:

https://bit.ly/2Yt45oD

Eric Dein @ericdeinmd( View Tweet )

Nov 09, 2021

#ACR21 L06 Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach https://t.co/4qo49lpBrt Video interview (https://t.co/k8PHCPaF1r) https://t.co/D4G2Ylkelm

Links:

Kazuki Yoshida @kaz_yos( View Tweet )

Nov 08, 2021

8M415 Gout Imaging Advances: Ralf Thiele on US🔊and DECT US>DECT: DECT needs a minimal density of MSU; DCS, tophi <2mm, liquid tophi may not be detected; US can show hyperemia DECT>US: DECT can show areas that may be overlooked from standard protocols 💡Bonus:stay around for Q&A https://t.co/G7yQaj9fHw

USSONAR @USSONAR_Rh( View Tweet )

Nov 08, 2021

Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to single measure in predicting incident gout over 9 years. Makes sense in general, maybe different in those with medication changes etc? Abstr#1449 #ACR21 @RheumNow https://t.co/69NofMNuB8

Richard Conway @RichardPAConway( View Tweet )

Nov 08, 2021

Rush on over to ‘DASH’ diet to ⬇️women at risk for gout abst#0991 #ACR21 @RheumNow it is low salt diet and ⤵️serum urate and HTN https://t.co/smQgVpV3BD

Janet Pope @Janetbirdope( View Tweet )

Nov 07, 2021

In general low health literacy has ⬆️association with non adherence in chronic disease Rx including gout prevention but many other reasons for non adherence cross the health literacy divide. Ex use of alternative Rx, denial, side effects, advice from non HCPs #ACR21 @RheumNow https://t.co/mIIndW1FnV

Links:

Eric Dein on Twitter: "#ACR21 Rheum Secrets and Pearls
Is it Allopurin…

Janet Pope @Janetbirdope( View Tweet )

Nov 07, 2021

#ACR21 Rheum Secrets and Pearls Is it Allopurinol or adherence concern? Oxypurinol can be helpful in measuring adherence! Kolfenbach: "I despise the term non-compliant patient." Address the many reasons why adherence may be low! Health literacy is key. @Rheumnow https://t.co/CPJ8kvqcCm

Eric Dein @ericdeinmd( View Tweet )

Nov 07, 2021

DECT (dual energy CT) very helpful to distinguish gout from other crystals and give volumetric measurements using color-coded images... So do we need to do arthrocentesis to diagnose gout anymore? #ACR21 https://t.co/kn2IpXP870

TheDaoIndex @KDAO2011( View Tweet )

Nov 06, 2021

Pearls on gout: 👉Gouty tophi can appear in the L spine and destroy the facet joints #ACR21 Radiology Bootcamp with Dr. Brindle. https://t.co/ml2uI9f10v

TheDaoIndex @KDAO2011( View Tweet )

Nov 06, 2021

Erosive polyarticular chronic tophaceous gout Regional Winner of East Asia and Pacific Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/1wrNAhjsw6

TheDaoIndex @KDAO2011( View Tweet )

Nov 06, 2021

Treat-to-Target Works in Gout With No Cardiac Toxicity
Save

ACR

Nov 04, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of

Read Article